arixtra sales

Arixtra 20 100 11 71 9 >100

Arixtra for Acute Coronary Syndromes (ACS) – Following receipt of an approvable letter from the FDA
in February, GSK submitted additional information to the agency during the quarter. Arixtra is also
under regulatory review for ACS in Europe.

Last week, GSK received approval for use of Arixtra to prevent venous thromboembolic events (VTE) in
Japan. Arixtra is the first new anti-thrombotic agent to be approved in Japan for VTE since the approval
of unfractionated heparin in 1972.
• • • • •